dulaglutide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
Glucagon-like Peptide (GLP) analogues 4885 923950-08-7

Description:

MoleculeDescription

Synonyms:

  • dulaglutide
  • trulicity
  • LY2189265
a glucagon-like peptide-1 receptor agonist; GLP-1 immunoglobulin G (IgG4) Fc fusion protein with extended activity
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
0.16 mg P

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Nov. 22, 2014 EMA
Sept. 18, 2014 FDA ELI LILLY AND CO

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Nausea 491.62 21.26 649 9550 704749 49890176
Blood glucose increased 458.22 21.26 242 9957 71082 50523843
Injection site pain 395.46 21.26 257 9942 110767 50484158
Accidental underdose 350.43 21.26 67 10132 591 50594334
Glycosylated haemoglobin increased 249.13 21.26 90 10109 10516 50584409
Diabetic ketoacidosis 203.62 21.26 90 10109 17782 50577143
Extra dose administered 201.93 21.26 64 10135 5012 50589913
Vomiting 193.22 21.26 337 9862 460421 50134504
Inappropriate schedule of product administration 186.11 21.26 137 10062 71694 50523231
Pancreatitis 152.02 21.26 99 10100 42515 50552410
Incorrect dose administered 145.21 21.26 101 10098 48313 50546612
Accidental overdose 135.62 21.26 70 10129 19463 50575462
Injection site haemorrhage 132.58 21.26 71 10128 21275 50573650
Product dose omission issue 123.86 21.26 168 10031 183670 50411255
Injection site pruritus 118.11 21.26 83 10116 40328 50554597
Abdominal pain upper 114.03 21.26 150 10049 159159 50435766
Diabetic metabolic decompensation 108.67 21.26 30 10169 1450 50593475
Injection site erythema 104.49 21.26 100 10099 74836 50520089
Injection site mass 88.58 21.26 49 10150 15631 50579294
Product administered at inappropriate site 81.65 21.26 27 10172 2416 50592509
Injection site bruising 79.40 21.26 63 10136 36705 50558220
Hypoglycaemia 77.49 21.26 73 10126 53508 50541417
Blood glucose abnormal 77.22 21.26 34 10165 6638 50588287
Diarrhoea 68.54 21.26 266 9933 588210 50006715
Injury associated with device 67.75 21.26 25 10174 3092 50591833
Underdose 67.12 21.26 45 10154 20233 50574692
Injection site rash 61.11 21.26 39 10160 16138 50578787
Euglycaemic diabetic ketoacidosis 55.40 21.26 21 10178 2798 50592127
Acute kidney injury 52.52 21.26 131 10068 227927 50366998
Transcription medication error 50.91 21.26 11 10188 186 50594739
Injection site urticaria 50.02 21.26 31 10168 12186 50582739
Blood glucose decreased 49.92 21.26 36 10163 18175 50576750
Lactic acidosis 47.35 21.26 45 10154 33310 50561615
Pancreatic carcinoma 45.22 21.26 23 10176 6191 50588734
Pancreatitis acute 39.39 21.26 35 10164 23777 50571148
Eructation 36.80 21.26 21 10178 7100 50587825
Ketoacidosis 36.08 21.26 17 10182 3878 50591047
Wrong technique in product usage process 34.63 21.26 49 10150 55461 50539464
Hyperglycaemic hyperosmolar nonketotic syndrome 33.95 21.26 10 10189 610 50594315
Diabetes mellitus inadequate control 33.79 21.26 25 10174 13120 50581805
Weight decreased 31.44 21.26 107 10092 221138 50373787
Systemic infection 30.90 21.26 13 10186 2270 50592655
Accidental exposure to product 30.63 21.26 30 10169 23027 50571898
Blood glucose fluctuation 29.16 21.26 15 10184 4131 50590794
Blood calcitonin increased 28.60 21.26 5 10194 25 50594900
Lipase increased 28.36 21.26 19 10180 8522 50586403
Thirst decreased 27.48 21.26 7 10192 247 50594678
Dehydration 27.40 21.26 80 10119 152369 50442556
COVID-19 27.36 21.26 40 10159 46622 50548303
Toxicity to various agents 27.16 21.26 5 10194 212494 50382431
Injection site swelling 26.24 21.26 37 10162 41736 50553189
Injection site injury 26.12 21.26 8 10191 558 50594367
Impaired gastric emptying 25.65 21.26 18 10181 8700 50586225
Hyperglycaemia 25.51 21.26 34 10165 36371 50558554
Coronavirus test positive 25.20 21.26 8 10191 628 50594297
Decreased appetite 23.30 21.26 91 10108 200832 50394093

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Blood glucose increased 357.57 22.16 218 8306 58766 29507237
Injection site pain 307.89 22.16 161 8363 32285 29533718
Accidental underdose 304.14 22.16 58 8466 335 29565668
Pancreatitis 238.49 22.16 139 8385 34375 29531628
Nausea 233.91 22.16 346 8178 288909 29277094
Inappropriate schedule of product administration 232.90 22.16 150 8374 44322 29521681
Glycosylated haemoglobin increased 200.48 22.16 82 8442 9344 29556659
Diabetic ketoacidosis 188.04 22.16 92 8432 15981 29550022
Extra dose administered 148.61 22.16 49 8475 3028 29562975
Diarrhoea 140.56 22.16 300 8224 332398 29233605
Diabetes mellitus inadequate control 119.96 22.16 62 8462 12072 29553931
Pancreatitis acute 117.05 22.16 78 8446 24307 29541696
Vomiting 116.54 22.16 214 8310 212046 29353957
Injection site mass 107.62 22.16 45 8479 5410 29560593
Accidental overdose 98.49 22.16 62 8462 17531 29548472
Incorrect dose administered 95.95 22.16 78 8446 32906 29533097
Euglycaemic diabetic ketoacidosis 88.58 22.16 32 8492 2598 29563405
Injection site erythema 87.82 22.16 53 8471 13903 29552100
Product dose omission issue 85.34 22.16 121 8403 96262 29469741
Injection site pruritus 85.28 22.16 39 8485 5810 29560193
Injection site haemorrhage 80.43 22.16 42 8482 8344 29557659
Obstructive pancreatitis 66.80 22.16 17 8507 413 29565590
Underdose 64.33 22.16 41 8483 11828 29554175
Weight decreased 57.38 22.16 131 8393 150774 29415229
Ketoacidosis 55.36 22.16 25 8499 3614 29562389
Eructation 53.07 22.16 25 8499 3981 29562022
Pancreatic carcinoma 52.45 22.16 30 8494 7120 29558883
Injection site swelling 49.72 22.16 32 8492 9385 29556618
Lipase increased 48.18 22.16 30 8494 8307 29557696
Lactic acidosis 47.91 22.16 51 8473 30196 29535807
Injection site discomfort 40.54 22.16 15 8509 1302 29564701
Abdominal pain 39.23 22.16 106 8418 135251 29430752
Injury associated with device 38.87 22.16 13 8511 838 29565165
Injection site bruising 35.73 22.16 24 8500 7556 29558447
Abdominal discomfort 34.93 22.16 55 8469 47848 29518155
Injection site rash 34.59 22.16 18 8506 3546 29562457
Blood glucose abnormal 33.76 22.16 20 8504 5063 29560940
Hypoglycaemia 33.18 22.16 54 8470 48292 29517711
Pancreatic carcinoma metastatic 33.05 22.16 16 8508 2705 29563298
Dyspepsia 32.95 22.16 42 8482 30083 29535920
Injection site reaction 31.52 22.16 26 8498 11162 29554841
Hyperkinetic heart syndrome 30.33 22.16 7 8517 111 29565892
Glycosylated haemoglobin abnormal 30.33 22.16 7 8517 111 29565892
Blood glucose decreased 29.81 22.16 26 8498 12043 29553960
Hyperlipasaemia 28.59 22.16 9 8515 478 29565525
Flatulence 28.28 22.16 30 8494 17679 29548324
Gastrointestinal disorder 28.26 22.16 38 8486 28668 29537335
Injection site urticaria 27.61 22.16 12 8512 1584 29564419
Gastric dilatation 27.31 22.16 9 8515 554 29565449
Acute kidney injury 27.19 22.16 149 8375 265118 29300885
Ketonuria 27.05 22.16 9 8515 571 29565432
Wrong drug 27.03 22.16 6 8518 79 29565924
Product storage error 26.99 22.16 19 8505 6451 29559552
Pneumonia 25.55 22.16 33 8491 320139 29245864
Injection site nodule 25.25 22.16 11 8513 1459 29564544
COVID-19 23.05 22.16 39 8485 35975 29530028

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Blood glucose increased 357.01 17.53 227 12257 97846 64388402
Diabetic ketoacidosis 325.65 17.53 144 12340 29701 64456547
Pancreatitis 241.93 17.53 148 12336 59459 64426789
Vomiting 208.61 17.53 377 12107 550740 63935508
Nausea 201.68 17.53 457 12027 785343 63700905
Glycosylated haemoglobin increased 199.81 17.53 85 12399 15934 64470314
Pancreatitis acute 177.88 17.53 108 12376 42747 64443501
Injection site pain 173.01 17.53 155 12329 111253 64374995
Euglycaemic diabetic ketoacidosis 148.32 17.53 51 12433 5359 64480889
Diabetes mellitus inadequate control 138.17 17.53 72 12412 21249 64464999
Accidental underdose 128.40 17.53 29 12455 633 64485615
Diarrhoea 128.00 17.53 366 12118 722338 63763910
Acute kidney injury 115.18 17.53 262 12222 448978 64037270
Lactic acidosis 108.41 17.53 92 12392 61318 64424930
Inappropriate schedule of product administration 97.38 17.53 104 12380 92182 64394066
Product dose omission issue 92.61 17.53 148 12336 194599 64291649
Ketoacidosis 87.48 17.53 37 12447 6826 64479422
Pancreatic carcinoma 84.75 17.53 41 12443 10332 64475916
Hypoglycaemia 78.84 17.53 92 12392 89800 64396448
Diabetic metabolic decompensation 75.87 17.53 26 12458 2702 64483546
Extra dose administered 71.69 17.53 32 12452 6718 64479530
Obstructive pancreatitis 66.21 17.53 17 12467 646 64485602
Lipase increased 64.11 17.53 38 12446 14364 64471884
Accidental overdose 60.67 17.53 51 12433 33506 64452742
Injection site pruritus 57.35 17.53 52 12432 37774 64448474
Toxicity to various agents 55.07 17.53 4 12480 363509 64122739
Incorrect dose administered 54.60 17.53 63 12421 60702 64425546
Injection site haemorrhage 52.57 17.53 41 12443 24237 64462011
Injection site erythema 51.57 17.53 66 12418 70734 64415514
Pancreatic carcinoma metastatic 48.52 17.53 20 12464 3458 64482790
Weight decreased 46.56 17.53 141 12343 285598 64200650
Underdose 46.16 17.53 39 12445 25790 64460458
Injury associated with device 45.28 17.53 18 12466 2835 64483413
Transcription medication error 45.03 17.53 11 12473 340 64485908
Eructation 42.87 17.53 25 12459 9166 64477082
COVID-19 40.18 17.53 56 12428 65084 64421164
Blood glucose decreased 39.45 17.53 34 12450 23089 64463159
Injection site mass 39.20 17.53 30 12454 17240 64469008
Abdominal pain 37.42 17.53 139 12345 312236 64174012
Hyperglycaemia 36.99 17.53 52 12432 60916 64425332
Ketonuria 36.42 17.53 12 12472 1105 64485143
Wrong technique in product usage process 35.88 17.53 53 12431 64921 64421327
Blood glucose abnormal 35.75 17.53 22 12462 8891 64477357
Injection site rash 34.98 17.53 27 12457 15715 64470533
Hyperkinetic heart syndrome 32.53 17.53 7 12477 121 64486127
Ketosis 30.12 17.53 10 12474 943 64485305
Blood glucose fluctuation 29.91 17.53 17 12467 5938 64480310
Dehydration 28.95 17.53 100 12384 216663 64269585
Injection site urticaria 28.90 17.53 21 12463 11160 64475088
Wrong drug 28.21 17.53 7 12477 231 64486017
Blood calcitonin increased 27.24 17.53 5 12479 36 64486212
Decreased appetite 27.11 17.53 117 12367 281172 64205076
Injection site bruising 26.61 17.53 34 12450 36339 64449909
Hyperlipasaemia 25.66 17.53 9 12475 1001 64485247
Gastric dilatation 24.31 17.53 9 12475 1169 64485079
Injection site nodule 24.09 17.53 12 12472 3218 64483030
Pneumonia 23.95 17.53 45 12439 559531 63926717
Systemic infection 23.51 17.53 13 12471 4308 64481940
Thirst decreased 22.43 17.53 6 12478 268 64485980
Coronavirus test positive 22.36 17.53 8 12476 943 64485305
Device difficult to use 22.19 17.53 17 12467 9781 64476467
Cholelithiasis 22.13 17.53 35 12449 45471 64440777
Product administered at inappropriate site 21.57 17.53 11 12473 3099 64483149
Impaired gastric emptying 21.55 17.53 16 12468 8788 64477460
Urine ketone body present 20.93 17.53 11 12473 3296 64482952
Accidental exposure to product 19.85 17.53 25 12459 26339 64459909
Flatulence 19.55 17.53 29 12455 35637 64450611
Hyperamylasaemia 19.10 17.53 7 12477 884 64485364
Dysuria 18.61 17.53 31 12453 42026 64444222
Lumbosacral radiculoplexus neuropathy 18.60 17.53 4 12480 69 64486179
Drug ineffective 18.42 17.53 92 12392 840155 63646093
Lichen planus 18.40 17.53 9 12475 2319 64483929
Injection site discomfort 18.37 17.53 11 12473 4230 64482018
Platelet count decreased 18.14 17.53 5 12479 167706 64318542
Febrile neutropenia 17.83 17.53 7 12477 187650 64298598
Hyperglycaemic hyperosmolar nonketotic syndrome 17.77 17.53 8 12476 1711 64484537

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A10BJ05 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Glucagon-like peptide-1 (GLP-1) analogues
FDA CS M0160181 Glucagon-Like Peptide 1
FDA MoA N0000020058 Glucagon-like Peptide-1 (GLP-1) Agonists
MeSH PA D007004 Hypoglycemic Agents
FDA EPC N0000178480 GLP-1 Receptor Agonist

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Diabetes mellitus type 2 indication 44054006 DOID:9352




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Glucagon-like peptide 1 receptor GPCR AGONIST DRUG LABEL DRUG LABEL

External reference:

IDSource
WTT295HSY5 UNII
D09889 KEGG_DRUG
4033739 VUID
N0000191089 NUI
4033739 VANDF
C3179549 UMLSCUI
CHEMBL2108027 ChEMBL_ID
DB09045 DRUGBANK_ID
9164 INN_ID
C555680 MESH_SUPPLEMENTAL_RECORD_UI
7638 IUPHAR_LIGAND_ID
1551291 RXNORM
228834 MMSL
30573 MMSL
d08290 MMSL
015693 NDDF
714080005 SNOMEDCT_US
714081009 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Trulicity HUMAN PRESCRIPTION DRUG LABEL 1 0002-1433 INJECTION, SOLUTION 0.75 mg SUBCUTANEOUS BLA 36 sections
Trulicity HUMAN PRESCRIPTION DRUG LABEL 1 0002-1433 INJECTION, SOLUTION 0.75 mg SUBCUTANEOUS BLA 36 sections
Trulicity HUMAN PRESCRIPTION DRUG LABEL 1 0002-1434 INJECTION, SOLUTION 1.50 mg SUBCUTANEOUS BLA 36 sections
Trulicity HUMAN PRESCRIPTION DRUG LABEL 1 0002-1434 INJECTION, SOLUTION 1.50 mg SUBCUTANEOUS BLA 36 sections
Trulicity HUMAN PRESCRIPTION DRUG LABEL 1 0002-2236 INJECTION, SOLUTION 3 mg SUBCUTANEOUS BLA 36 sections
Trulicity HUMAN PRESCRIPTION DRUG LABEL 1 0002-2236 INJECTION, SOLUTION 3 mg SUBCUTANEOUS BLA 36 sections
Trulicity HUMAN PRESCRIPTION DRUG LABEL 1 0002-3182 INJECTION, SOLUTION 4.50 mg SUBCUTANEOUS BLA 36 sections
Trulicity HUMAN PRESCRIPTION DRUG LABEL 1 0002-3182 INJECTION, SOLUTION 4.50 mg SUBCUTANEOUS BLA 36 sections
Trulicity HUMAN PRESCRIPTION DRUG LABEL 1 50090-3483 INJECTION, SOLUTION 1.50 mg SUBCUTANEOUS BLA 35 sections
Trulicity HUMAN PRESCRIPTION DRUG LABEL 1 50090-3484 INJECTION, SOLUTION 0.75 mg SUBCUTANEOUS BLA 35 sections
Trulicity HUMAN PRESCRIPTION DRUG LABEL 1 50090-5467 INJECTION, SOLUTION 3 mg SUBCUTANEOUS BLA 35 sections